NEW YORK, Dec. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=180979&from=4 CLASS PERIO ...

Core Insights - Novo Nordisk's stock has significantly declined, losing over two-thirds of its value since mid-2024, despite initial excitement over its GLP-1 weight loss drugs [1] - Eli Lilly's weight loss drug tirzepatide has outperformed Novo Nordisk, with Zepbound sales increasing by 185% year over year in Q3, while Novo Nordisk reported only 12% sales growth in its obesity treatment and diabetes care operations [3] - Pfizer is making aggressive moves to re-enter the GLP-1 market, indicating a potential investment opportunity as it seeks to recover from recent pressures [4][7] Industry Dynamics - The pharmaceutical industry faces challenges in developing new drug candidates, which is a costly and complex process [1] - Being first to market does not guarantee success, as differences in drug effects, costs, and outcomes can significantly impact market performance [2] - Eli Lilly currently holds the leading position in the GLP-1 weight loss space, demonstrating that early leadership does not ensure sustained market dominance [6]

Core Points - Incyte Japan has received approval for Minjuvi® (tafasitamab) in combination with Rituximab and Lenalidomide for the treatment of relapsed/refractory follicular lymphoma [1] Company Summary - The approval of Minjuvi® marks a significant advancement in the treatment options available for patients with relapsed/refractory follicular lymphoma, indicating a potential increase in market share for Incyte Japan [1] - This combination therapy may enhance treatment efficacy and improve patient outcomes, positioning Incyte Japan favorably within the oncology market [1] Industry Summary - The approval reflects ongoing innovation in the oncology sector, particularly in the treatment of lymphomas, which is a growing area of focus for pharmaceutical companies [1] - The combination of therapies like Minjuvi®, Rituximab, and Lenalidomide may set a new standard of care, influencing future treatment protocols and competitive dynamics in the industry [1]

Core Points - Incyte Japan has received approval for Zynyz® (retifanlimab) as a first-line treatment for advanced anal cancer [1] Company Summary - The approval of Zynyz® marks a significant advancement in the treatment options available for patients with advanced anal cancer [1] - This development is expected to enhance Incyte's position in the oncology market, particularly in Japan [1] Industry Summary - The approval reflects ongoing innovation in cancer therapies, highlighting the importance of targeted treatments in oncology [1] - The move aligns with the growing trend of developing specialized therapies for specific cancer types, which is becoming increasingly prevalent in the pharmaceutical industry [1]

Core Viewpoint - The pharmaceutical company announced that its ceralasertib combination did not achieve the primary objective in a late-stage clinical trial for advanced lung cancer [1] Group 1 - The clinical trial was focused on advanced lung cancer [1] - The primary goal of the trial was not met, indicating potential challenges in the drug's efficacy [1]

Group 1: Novartis - Novartis is a strong long-term investment candidate due to its innovative pipeline and diversified product offerings, with 10 products generating over $1 billion in sales each as of September 30 [4][5] - The company has shown resilience against patent cliffs, with a revenue increase of 8% year-over-year to $13.9 billion and earnings per share of $2.25, which is 9% higher than the previous year [6][7] - Novartis has a solid dividend history, increasing payouts for 28 consecutive years, currently offering a forward yield of 3%, significantly higher than the S&P 500 average of 1.2% [10] Group 2: Shopify - Shopify has experienced a 50% stock increase this year, driven by strong financial results and a vision to build a sustainable 100-year company [11] - The platform is a leader in the e-commerce market, providing customizable templates and a range of services that facilitate efficient business operations for merchants [12] - Shopify's market share grew from 10% at the end of 2023 to 12% by the end of 2024, benefiting from high switching costs for merchants [14] - The company has improved its profitability, achieving net income in three out of the last four quarters, positioning itself well for continued dominance in the e-commerce sector [15]

Core Viewpoint - AstraZeneca announced that a late-stage trial of Imfinzi combined with ceralasertib did not show an improvement in overall survival for patients with previously treated advanced non-small cell lung cancer [1] Group 1 - The trial aimed to evaluate the efficacy of Imfinzi in combination with ceralasertib [1] - The patient population consisted of those with advanced non-small cell lung cancer who had previously undergone treatment [1] - The failure of the trial may impact AstraZeneca's strategy in the oncology sector [1]

Core Insights - The U.S. FDA has approved Genentech's CD20xCD3 bispecific Lunsumio VELO (mosunetuzumab-axgb) as a subcutaneous formulation for treating adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy [1] Company Summary - Genentech is a member of the Roche Group and has received FDA approval for a new treatment option targeting a specific patient population [1] Industry Summary - The approval is based on results from the Phase I/II GO29781 study, indicating a significant advancement in the treatment landscape for follicular lymphoma [1]

Core Viewpoint - Roche's Lunsumio VELO™ (mosunetuzumab) has received FDA approval as a subcutaneous treatment for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, based on the phase I/II GO29781 study results [1][3][4] Group 1: FDA Approval and Treatment Benefits - The FDA approval is based on the results from the GO29781 study, which demonstrated an objective response rate of 75% and a complete response rate of 59% in patients treated with Lunsumio VELO [3][7] - Lunsumio VELO significantly reduces treatment administration time to approximately one minute, compared to the previous 2-4 hour intravenous infusion, thus aligning treatment with patient needs [2][7] - The treatment can be administered in outpatient settings and is designed for a fixed duration, potentially as short as six months, contrasting with indefinite treatment options [2][3] Group 2: Clinical Study Insights - The GO29781 study evaluated the safety, efficacy, and pharmacokinetics of mosunetuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, establishing efficacy based on objective response rate and duration of response [6] - The median duration of response for Lunsumio VELO was reported as 22.4 months [3] - The most common adverse reactions (≥20%) included injection site reactions, fatigue, rash, and cytokine release syndrome (CRS), with a CRS rate of 30% primarily occurring during Cycle 1 [3][4] Group 3: Ongoing Research and Development - Roche is advancing its bispecific antibody program in lymphoma, with ongoing phase III studies evaluating Lunsumio and Lunsumio VELO in earlier lines of treatment [5] - The SUNMO study is investigating Lunsumio VELO in combination with Polivy® for second-line or later large B-cell lymphoma, while the MorningLyte study is exploring its use with lenalidomide in previously untreated follicular lymphoma [5] Group 4: Follicular Lymphoma Overview - Follicular lymphoma (FL) is the most common slow-growing form of non-Hodgkin lymphoma, accounting for about 20% of cases, and is characterized by periods of remission and relapse [8] - More than 110,000 people are diagnosed with FL each year worldwide, and the disease typically becomes harder to treat with each relapse [8]

Core Insights - The ongoing surge in IPOs is significantly utilizing mutual fund liquidity, with six primary market issuances accounting for over ₹13,000 crore in net equity investments by mutual funds in November [3][4]. Group 1: Mutual Fund Activity - Groww led the inflows, attracting approximately ₹4,200 crore, while other companies like Lenskart Solutions, Pine Labs, and Physics Wallah each garnered over ₹1,000 crore in investments from mutual funds [4]. - Net equity investments by mutual funds reached ₹43,500 crore in November, indicating strong demand and liquidity in the market [4]. Group 2: IPO Market Dynamics - The robust appetite for IPOs from mutual funds, alongside strong demand from other investor segments, has facilitated record issuances, with over 100 mainboard IPOs launched this year, the highest in 25 years [5]. - The primary market activity is largely driven by retail inflows into mutual funds, as elevated valuations in the secondary market have redirected liquidity towards primary issuances [5]. Group 3: Sector Trends - Demand in the primary market is particularly strong for consumer technology and new-age businesses, which currently represent 20% of recent IPOs, a figure expected to rise above 30% in the next five years [7][8]. - At least 20 startups with private market valuations in the hundreds of millions of dollars are preparing to enter the market, indicating a growing trend in the consumertech sector [8]. Group 4: Secondary Market Activity - In the secondary market, Eternal topped the mutual fund buy list with ₹4,500 crore invested, followed by ICICI Bank, ITC, Mphasis, and HDFC Bank [9]. - Conversely, mutual funds reduced their exposure to public sector banks and pharmaceutical stocks, with State Bank of India and Reliance Industries among the most sold stocks [9].